McKesson (MCK) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
The drug distributor raised its fiscal 2027 adjusted earnings guidance from $44.20 to $45.00 as second-quarter revenue rose 8% to $111.0 billion.
SEC Filings
A foreign tax-asset release cut McKesson's tax bill in the quarter, while class actions over a cybersecurity incident reached a Texas federal court.
Earnings
McKesson also closed its roughly $2.25 billion Precision Medicine Group purchase and raised its fiscal 2027 profit outlook.